Sam-A Pharm. Co., Ltd.

As of March 31, 2026, Sam-A Pharm. Co., Ltd. carries a market capitalization of 96.43B, placing it among publicly traded companies globally. Its enterprise value stands at -344.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Sam-A Pharm. Co., Ltd. has 6.10M shares outstanding.

As of March 31, 2026, Sam-A Pharm. Co., Ltd. trades at a trailing price-to-earnings ratio of 10.85. The price-to-sales ratio is 1.36, and the price-to-book ratio stands at 0.43.

As of March 31, 2026, Sam-A Pharm. Co., Ltd. maintains a current ratio of 7.79, meaning it holds 7.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Sam-A Pharm. Co., Ltd. posted a return on equity (ROE) of 3.97, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.03 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.53, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.83, useful for judging operating efficiency across full business cycles. The company generates approximately 226.61M in revenue per employee across its workforce of 313.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.92 indicates how many times Sam-A Pharm. Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Sam-A Pharm. Co., Ltd. recorded 1.61B in income tax expense. That works out to an effective tax rate of 15.38, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 10.50B, leaving 8.89B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Sam-A Pharm. Co., Ltd.'s stock has declined approximately 19.53% over the past 52 weeks. The 50-day moving average sits at 13,853.60, while the 200-day moving average is 14,634.70.

Over the twelve months ended March 31, 2026, Sam-A Pharm. Co., Ltd. generated 70.93B in revenue and converted that into 8.89B in net income, yielding earnings per share of 1,456.01. EBITDA reached 9.81B, while operating income came in at 5.62B.

As of March 31, 2026, Sam-A Pharm. Co., Ltd. holds 102.19B in cash and equivalents against 5.41B in total debt, resulting in a net debt position of -13.53B. Total book value stands at 225.89B, with working capital of 120.22B providing operational flexibility.

Sam-A Pharm. Co., Ltd. produced 9.72B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -2.08B in capital expenditures, free cash flow totaled 7.64B - equivalent to 1,251.93 per share.

Over the twelve months ended March 31, 2026, Sam-A Pharm. Co., Ltd. posted a gross margin of 57.13, reflecting its pricing power and cost economics. The operating margin of 7.93 and net profit margin of 12.53 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Sam-A Pharm. Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 7.92, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 11.56, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sam-A Pharm. Co., Ltd. shareholders.

Sam-A Pharm. Co., Ltd.'s most recent stock split took place on December 29, 2008 with a 349:356 split ratio.

As of March 31, 2026, Sam-A Pharm. Co., Ltd. has an Altman Z-Score of 4.72, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.